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Recent studies on BAFF, a member of the tumor
necrosis factor family, and the discovery of a new BAFF
receptor have revealed that this ligand–receptor pair is
essential for B-cell survival and differentiation, holding
promise for a better understanding and treatment of
some autoimmune diseases and lymphomas.
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Members of the tumor necrosis factor (TNF) cytokine
family regulate a wide range of biological responses, such
as inflammation and apoptosis. The recent discovery of a
new member of the TNF family, BAFF, and the identifi-
cation of its receptors, together with the description of
their functions in immune responses, reads like a gripping
detective story. It has also sparked a competitive race
between biotechnology companies hoping to use this infor-
mation to design drugs for the treatment of certain autoim-
mune diseases and lymphoma [1]. BAFF (also called BLys,
TALL-1, THANK, zTNF4) was discovered in 1999 as a
TNF-related cytokine by sequence-homology-based data-
base searches [2,3]. Two receptors for BAFF were identi-
fied soon after [1] but it was clear that there was more to
the story. Now a number of papers (including one in this
issue of Current Biology) describe a new important receptor
for BAFF and provide interesting insights into the role of
BAFF in B-cell survival [4–7].
BAFF is produced by macrophages, dendritic cells and
T lymphocytes. It promotes survival of B cells in culture
and increases their proliferation in response to mitogenic
stimulation [2,3]. Expression of a BAFF transgene in mice
caused accumulation of immature and mature B cells,
increased serum immunoglobulin (Ig) levels and elicited
systemic lupus erythematosus (SLE)-like autoimmune
symptoms [8–10]. BAFF therefore promotes survival and
differentiation of autoreactive B cells, which would nor-
mally be deleted at the B-cell receptor checkpoint. In con-
trast, BAFF-deficient mice have a profound block in B-cell
development at the B-cell receptor checkpoint [4,11]. These
mice have normal numbers of short-lived pro-B, pre-B and
immature B cells but failed to accumulate mature B cells
(Table 1). Thus, BAFF is essential for the transition through
the B-cell receptor checkpoint and for sustained survival
of long-lived B cells. BAFF-deficient mice also have pro-
found defects in antibody-mediated immune responses
and abnormally low serum Ig levels. It is unclear whether
this defect reflects a role for BAFF in B-cell activation or is
simply a consequence of the shortage of antigen-reactive
B cells in these mice.
APRIL (also called TRDL-1α), another TNF family
member found by database mining [12], is the closest
known relative of BAFF and is produced by macrophages.
APRIL stimulates proliferation of transformed cells and,
intriguingly, high levels of APRIL have been detected in
many types of cancers. These findings may indicate that
APRIL plays a role in tumorigenesis, either as an autocrine
growth factor or perhaps to stimulate angiogenesis.
At the time of the discovery of BAFF and APRIL, two
members of the TNF receptor family — BCMA and TACI
— were recognized as ‘orphan receptors’. Typically TNF
receptor family members contain in their extracellular region
several modules containing six cysteines that form three
disulfide bonds. TACI and BCMA are most closely related
to each other, but are unique in that BCMA has only one
such module in its ligand-binding region, while TACI has
two. Studies with recombinant proteins identified ligands
for these receptors and demonstrated that BAFF and
APRIL interact with both TACI and BCMA, but not with
the other TNF receptor family members known at that
time [9,13–15]. These receptor–ligand interactions are of
significant affinity, because injection or transgenic expres-
sion of soluble forms of the TACI and BCMA receptors
achieved effective ligand neutralization that was sufficient
to dampen antibody-mediated immune responses ([9,15]
and J. Tschopp, personal communication).
It was therefore thought that TACI and BCMA represent
essential receptors for BAFF and APRIL. However, there
were inklings that matters may not be that simple. For
example, BAFF and APRIL could bind to certain cell
lines that expressed neither TACI nor BCMA [5,12]. Nev-
ertheless, it came as a surprise that TACI- and BCMA-
deficient mice have no major defect in the antigen-
independent stages of B-cell development (Table 1). No
B-cell abnormalities were found in BCMA-deficient mice
[4,16]. Surprisingly, TACI-deficient mice even had mild
B-cell hyperplasia [17,18], indicating that TACI may
inhibit B-cell production by acting as a decoy receptor for
BAFF. Interestingly, TACI-deficient mice had impaired
responses to so-called type II T-cell-independent (TI)
antigens (prototypically NP-Ficoll) but normal antibody-
mediated responses to all other types of antigens. Responses
to type I TI antigens, such as lipopolysaccharide, may be
independent of TACI, because they, unlike type II TI
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antigens, can activate Toll-like receptors. Interestingly,
Toll-like receptors and TNF receptor family members
stimulate some of the same transcription factors, for
example Rel/NF-κB, indicating that they may have over-
lapping functions.
The striking defect in B-cell production in BAFF-defi-
cient mice compared to the (near) normal B lymphopoiesis
in TACI-deficient and BCMA-deficient mice may have
been explained by functional overlap between these two
receptors. However, the recent discoveries by two indepen-
dent groups (one published in Current Biology) of a third
BAFF receptor — BAFF-R, also called BR3 — provided a
different resolution for this conundrum [5,6]. Like TACI,
BAFF-R is a type III transmembrane protein. The extra-
cellular ligand-binding domain of BAFF-R has only a
single cysteine-rich domain which contains only four
rather than the characteristic six cysteine residues.
Although this makes BAFF-R a very distant member of
the TNF receptor family, it is anticipated that its three-
dimensional structure will be similar to that of its relatives.
Remarkably, both groups [5,6] discovered BAFF-R by
expression library screening using BAFF as bait, but failed
to discover the gene in database searches using profiles
specific for TNF-receptors. This demonstrates that func-
tional screens for gene discovery can sometimes be supe-
rior to database mining, even after completion of the human
and mouse genome projects.
BAFF-R expression was detected in resting B cells [5,6],
consistent with a role for BAFF–BAFF-R signaling in the
transition from the immature to the mature B cell stage.
Injection of soluble BAFF-R proteins into mice diminished
IgG1 antibody production [6]. This may indicate that
BAFF–BAFF-R signaling is critical for the initiation of
B-cell activation whereas CD40L–CD40 stimulation is
essential to sustain activation. Since BAFF-R binds only to
BAFF and not to APRIL [5,6], this demonstrates that
BAFF alone and not APRIL plays a role in B-cell activa-
tion. So, do APRIL and BCMA have any role in B lym-
phopoiesis? BCMA is most highly expressed in Ig-secreting
plasma cells [1]. It is therefore tempting to speculate that
APRIL–BCMA signaling is critical for survival of those
plasma cells in the bone marrow that contribute to long-
term memory to infection or immunization.
Genetic and phenotypic analysis of a spontaneous mutant
mouse strain (A/WySnJ) with defective production and
survival of B cells, demonstrated that BAFF-R is the criti-
cal receptor for BAFF during B lymphopoiesis [5–7].
A/WySnJ mice have an insertion in bcmd, the gene encod-
ing BAFF-R, and this results in expression of a mutant
BAFF-R lacking the last eight amino acids in its intracellu-
lar region but retaining normal binding to BAFF [5–7].
This missing region has striking similarity to a correspond-
ing region in BCMA, indicating that these two receptors
may activate similar signaling pathways.
As the A/WySnJ mutant BAFF-R is expressed on the
cell surface and does bind BAFF, it could potentially act
as a dominant-interfering mutant that blocks not only
BAFF–BAFF-R signaling but also impedes signals from
other (related) receptors. If this were the case, the pheno-
type of A/WySnJ mutant mice might be more severe than
Table 1
Immunological phenotypes of selected relevant knockout and transgenic mouse models.
Mouse system Bone marrow- Late transitional Mature Serum IgG Serum IgM TD-I* TI-I†
pro/pre-B cells B cells B cells
baff–/– [4,11] Normal – – – – – –
“baff-r–/–” (A/WySnJ) [5] Normal n.a.‡ – – Normal – Normal
taci–/– [17,18] Normal + ++ Normal Abnormal Normal –
bcma–/– [4,16] Normal n.a Normal Normal Normal Normal Normal
taci-Ig tg§ [11,15] Normal – – – – – –
nik–/– (aly-mice) [22] n.a. – – – – – n.a.
ikk-α–/– [23,24] Normal – – – – – n.a.
c-rel–/–/rel-a–/– [25] n.a. – – n.a. n.a. n.a. n.a.
baff tg [8–10] Normal +++ +++ +++ +++ ++ +++
bcl-2 tg [19] Normal ++ ++ ++ ++ ++ n.a.
bim–/– [20] Normal ++ ++ ++ ++ n.a. n.a.
*TD-I (T-cell-Dependent Immune responses). †TI-I (T-cell-Independent Immune responses; type II). ‡n.a. not analysed, not reported. §tg transgenic.
that of BAFF-deficient mice. In fact, the opposite is the
case — A/WySnJ mice produce more B cells than BAFF-
deficient mice [5–7,11], indicating that the baff-r mutation
in A/WySnJ mice represents a partial loss-of-function
mutation that retains some signaling function.
So, how does BAFF-R signal? It is noteworthy that the
effects of BAFF overexpression — prolonged survival and
accumulation of B cells, and autoimmunity [8–10] — mimic
those observed in transgenic mice overexpressing the pro-
survival protein Bcl-2 [19] or those lacking its antagonist
Bim [20]. Conversely, the B-cell phenotype of BAFF-defi-
cient and baff-r mutant mice is very similar to that caused
by Bcl-2 deficiency [21], loss of the NF-κB-inducing
kinase NIK in aly-mice [22] or the IκB kinase IKKα [23,24],
or combined loss of the Rel/NF-κB transcription factors
c-Rel and RelA [25]. Reduced levels of Bcl-2 were found
in c-Rel/RelA-deficient B cells and expression of a bcl-2
transgene almost completely rescued the B-cell defect
caused by loss of IKKα [24] or c-Rel/RelA [25]. We there-
fore speculate that BAFF-R promotes B-cell survival by
upregulation of Bcl-2 expression mediated by Rel/NF-κB
transcription factors (Figure 1): it will be interesting to see
if a bcl-2 transgene or loss of Bim can restore normal B-cell
production in BAFF-deficient or BAFF-R-deficient
(A/WySnJ) mice.
The importance of BAFF and BAFF-R in controlling the
transition of B cells through the B-cell receptor checkpoint
makes one wonder whether other members of the TNF
family and their receptors might regulate survival and dif-
ferentiation of T lymphocytes at the transition from the
immature CD4+CD8+ to the mature (CD4+CD8– or
CD4–CD8+) stages. Several other questions are raised by
these interesting discoveries. For example, what are the
functions of APRIL and BCMA? It is unlikely that APRIL
has evolved to promote tumorigenesis, but because it stim-
ulates growth of epithelial cancers [12,15] their normal
counterparts may be the physiological targets of APRIL.
Apparently, these cells express neither BCMA nor TACI
[15], indicating that APRIL might have a third receptor,
perhaps similar in structure to BAFF-R. The generation of
mice lacking APRIL or all of its receptors is expected to
unravel the mystery of its physiological function.
Certainly, the demonstration that soluble decoy receptors
for BAFF and APRIL can inhibit SLE-like autoimmunity
[9] and rheumatoid arthritis [11,26] in susceptible mouse
strains and reduce growth of human cancer cell xenografts
[15] will further accelerate the race for drugs that inhibit
the function of these intriguing molecules.
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Figure 1
BAFF preferentially binds to BAFF-R and TACI (thick arrows) and
interacts with BCMA more weakly (thin arrow). In contrast, APRIL
binds more avidly to BCMA than to TACI and does not bind to BAFF-R.
We speculate that a third APRIL receptor exists and expect it to be
expressed on epithelial cells. Direct evidence has been presented
regarding the signaling cascades that can be activated by TACI and
BCMA [1]. So far, nothing has been published on the signaling
pathways activated by BAFF-R, but genetic evidence points towards
NIK- and IKKα-mediated NF-κB activation which causes upregulation
of anti-apoptotic Bcl-2 family members. Sequence homology within the
intracellular domains of BAFF-R and BCMA indicate that these two
receptors activate similar signaling pathways (although the outcome of
BCMA signaling is less clear). TRAF, TNF receptor-associated factor;
JNK, c-Jun N-terminal kinase; NF-AT, nuclear factor of activated T cells;
CAML, calcium modulator and cyclophilin ligand.
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